These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32424550)

  • 1. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens.
    Ueyama H; Kuno T; Takagi H; Alvarez P; Asleh R; Briasoulis A
    Heart Fail Rev; 2022 May; 27(3):869-877. PubMed ID: 32424550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis.
    Jennings DL; Lange N; Shullo M; Latif F; Restaino S; Topkara VK; Takeda K; Takayama H; Naka Y; Farr M; Colombo P; Baker WL
    Int J Cardiol; 2018 Aug; 265():71-76. PubMed ID: 29605470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients.
    Rosenthal LM; Nordmeyer J; Kramer P; Danne F; Pfitzer C; Berger F; Schmitt KRL; Schubert S
    Pediatr Transplant; 2021 Dec; 25(8):e14111. PubMed ID: 34405495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors.
    Gottlieb J; Fischer B; Schupp JC; Golpon H
    PLoS One; 2023; 18(5):e0284653. PubMed ID: 37200246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
    Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
    Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
    Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
    Deng J; Lu Y; He L; Ou J; Xie H
    Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.